Composition of anthracycline antineoplastic drug and platinum antineoplastic drug and preparation method thereof
According to the composition of the anthracycline antineoplastic drug and the platinum antineoplastic drug and the preparation method of the composition, EP and OXP are limited in a fixed proportion, the drug effect can be improved, or two kinds of drugs represented by the EP and the OXP are jointly entrapped in a nanoparticle carrier, such as lipidosome, according to a fixed synergistic ratio, the limitation of traditional chemotherapy can be broken through, and the drug effect can be improved. According to the present invention, the two drugs can maintain the synergistic specific drug loading, drug delivery and drug release in the body for a long time, and are accumulated in the tumor in the targeting manner, such that the drug effect can be significantly improved, the synergistic effect and toxicity reducing target can be achieved, the patient can be benefited, and the treatment drug with characteristics of good treatment effect, good safety and good drug compliance can be provided for the clinic..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 11. Juli Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
ZHUANG YI [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-07-11, Last update posted on www.tib.eu: 2023-11-28, Last updated: 2023-12-01 |
|---|
| Patentnummer: |
CN116407548 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA018202012 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA018202012 | ||
| 003 | DE-627 | ||
| 005 | 20231201094624.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231013s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA018202012 | ||
| 035 | |a (EPA)CN116407548 | ||
| 035 | |a (EPA)87050198 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a ZHUANG YI |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Composition of anthracycline antineoplastic drug and platinum antineoplastic drug and preparation method thereof |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-07-11, Last update posted on www.tib.eu: 2023-11-28, Last updated: 2023-12-01 | ||
| 520 | |a According to the composition of the anthracycline antineoplastic drug and the platinum antineoplastic drug and the preparation method of the composition, EP and OXP are limited in a fixed proportion, the drug effect can be improved, or two kinds of drugs represented by the EP and the OXP are jointly entrapped in a nanoparticle carrier, such as lipidosome, according to a fixed synergistic ratio, the limitation of traditional chemotherapy can be broken through, and the drug effect can be improved. According to the present invention, the two drugs can maintain the synergistic specific drug loading, drug delivery and drug release in the body for a long time, and are accumulated in the tumor in the targeting manner, such that the drug effect can be significantly improved, the synergistic effect and toxicity reducing target can be achieved, the patient can be benefited, and the treatment drug with characteristics of good treatment effect, good safety and good drug compliance can be provided for the clinic. | ||
| 650 | 4 | |a tec | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a phy | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a B82Y: Specific uses or applications of nanostructures; measurement or analysis of nanostructures; manufacture or treatment of nanostructures | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a CHENG GUANG |4 aut | |
| 700 | 0 | |a ZHANG GUOMIN |4 aut | |
| 700 | 0 | |a CONG ZHONGCHENG |4 aut | |
| 700 | 0 | |a ZHU PANJIE |4 aut | |
| 700 | 0 | |a XI WANG |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 11. Juli |
| 773 | 1 | 8 | |g year:2023 |g day:11 |g month:07 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/87050198/publication/CN116407548A1?q=CN116407548 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 11 |c 07 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 11 |c 07 | ||